Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $86.10 USD
Change Today +0.10 / 0.12%
Volume 3.4M
ESRX On Other Exchanges
Symbol
Exchange
ESRX is not on other exchanges.
As of 8:10 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

express scripts holding co (ESRX) Snapshot

Open
$85.49
Previous Close
$86.00
Day High
$86.16
Day Low
$85.30
52 Week High
05/22/15 - $91.21
52 Week Low
07/23/14 - $65.08
Market Cap
62.8B
Average Volume 10 Days
5.0M
EPS TTM
$3.37
Shares Outstanding
729.3M
EX-Date
--
P/E TM
25.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for EXPRESS SCRIPTS HOLDING CO (ESRX)

express scripts holding co (ESRX) Details

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company operates through two segments, PBM and Other Business Operations. The company’s PBM segment’s services include clinical solutions to enhance health outcomes, such as adherence, case coordination, and personalized medicine; specialized pharmacy care; home delivery pharmacy; specialty pharmacy, including the distribution of fertility pharmaceuticals that require special handling or packaging; and retail network pharmacy administration. It also provides benefit design consultation; drug utilization review; drug formulary management; an array of Medicare, Medicaid, and health insurance marketplace; administration of a group purchasing organization; and consumer health and drug information services. In addition, the company distributes specialty pharmaceuticals and medical supplies to providers, clinics, and hospitals; and offers consulting services for pharmaceutical manufacturers to collect scientific evidence to guide the use of medicines, as well as case management approach to manage care by integrating pre-certification, case management, and discharge planning services for patients. It serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans, government health programs, office-based oncologists, renal dialysis clinics, ambulatory surgery centers, primary care physicians, retina specialists, and others. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in St. Louis, Missouri.

29,500 Employees
Last Reported Date: 02/23/15
Founded in 1986

express scripts holding co (ESRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.2M
President
Total Annual Compensation: $1.3M
Executive Vice President and General Counsel
Total Annual Compensation: $660.4K
Chief Human Resources Officer and Senior Vice...
Total Annual Compensation: $535.4K
Vice President
Total Annual Compensation: $332.0K
Compensation as of Fiscal Year 2014.

express scripts holding co (ESRX) Key Developments

New York Police Union Lawsuit against Express Scripts Gets New Life

A class action lawsuit against Express Scripts filed by a New York City police union has won reinstatement. The suit accused Express Scripts of suggesting patients use more expensive drugs to grow profits. On May 27, 2015, Judge William Benton of the 8th U.S. Circuit Court of Appeals said the police union's suit was not affected by a 2008 settlement between Express Scripts and New York's attorney general. The suit was revived because its claims were not included in the 2008 settlement. In April, the pharmacy benefits manager Express Scripts said its profit had increased 34% during the first quarter of 2015 to $441.1 million over the same period in 2014.

Express Scripts Holding Company Presents at Sanford C. Bernstein Thirty-First Annual Strategic Decisions Conference 2015, May-27-2015

Express Scripts Holding Company Presents at Sanford C. Bernstein Thirty-First Annual Strategic Decisions Conference 2015, May-27-2015 . Venue: The Waldorf Astoria Hotel, 301 Park Avenue (between 49th and 50th Street), New York, New York, United States.

Express Scripts Holding Co. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for Second Quarter Ending June 2015 and Full Year Ending December 31, 2015

Express Scripts Holding Co. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, revenues were $24,899.6 million compared to $23,685.0 million a year ago. Income before income taxes was $715.5 million compared to $595.8 million a year ago. Net income was $447.1 million compared to $334.5 million a year ago. Net income attributable to company was $441.1 million or $0.60 diluted per share compared to $328.3 million or $0.42 diluted per share a year ago. Net cash flows provided by operating activities was $281.4 million compared to $454.0 million a year ago. Purchases of property and equipment were $48.3 million compared to $117.1 million a year ago. Adjusted EBITDA attributable to company was $1,512.1 million or $4.92 per share compared to $1,471.0 million or $4.60 per share a year ago. Diluted EPS attributable to company, adjusted was $1.10 compared to $0.99 a year ago. Adjusted net income attributable to company was $811.1 million compared to $779.2 million a year ago. For the current quarter ending in June, the company expects its per-share earnings to range from $1.39 to $1.43, up 13% to 16% year-over-year. Adjusted claims expect to range from $310 million to $330 million. The company narrowed its adjusted earnings per diluted share guidance from a range of $5.35 to $5.49 to a range of $5.37 to $5.47, which maintains the mid-point of $5.42. The new guidance range represents growth of 10% to 12% over 2014. The company anticipates full-year 2015 integration costs to be approximately $250.0 million, but the exact amount is indeterminable.  The company is unable to include these charges in the list of GAAP items not included in guidance for 2015 full-year earnings per diluted share attributable to company, adjusted selling, general and administrative, adjusted EBITDA and adjusted EBITDA per adjusted claim or to provide a reconciliation to the corresponding GAAP measure.  2015 Adjusted EPS will exclude amortization of intangible assets per diluted share in the range of $1.52 to $1.56.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESRX:US $86.10 USD +0.10

ESRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Anthem Inc $164.14 USD -3.93
Cardinal Health Inc $88.03 USD -0.39
McKesson Corp $236.62 USD -1.65
Kroger Co/The $72.30 USD -0.69
Walgreens Boots Alliance Inc $86.33 USD +0.35
View Industry Companies
 

Industry Analysis

ESRX

Industry Average

Valuation ESRX Industry Range
Price/Earnings 30.3x
Price/Sales 0.6x
Price/Book 3.0x
Price/Cash Flow 29.6x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXPRESS SCRIPTS HOLDING CO, please visit www.express-scripts.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.